Search research articles
Contact Us
Filters
Showing results (31-40 of 33) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 33 results.
The New England Journal of Medicine
|
September 20, 2007
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W Lyles, Cathleen S Colón-Emeric, Jay S Magaziner, et al.
Arthritis Research & Therapy
|
February 26, 2016
Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoarthritis Study
Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Trine Jensen, et al.
Lancet (London, England)
|
July 31, 2017
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L Langdahl, Cesar Libanati, Daria B Crittenden, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 33) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 33 results.
The New England Journal of Medicine
|
September 20, 2007
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W Lyles, Cathleen S Colón-Emeric, Jay S Magaziner, et al.
Arthritis Research & Therapy
|
February 26, 2016
Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoarthritis Study
Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Trine Jensen, et al.
Lancet (London, England)
|
July 31, 2017
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L Langdahl, Cesar Libanati, Daria B Crittenden, et al.
Page
of 4